SYT-510

SYT-510
Clinical data
Routes of; administration	Endocannabinoid reuptake inhibitor

SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders.^[1]^[2]^[3]^[4] It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target.^[4]^[1] As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications.^[1]^[2]^[4]^[3] It is under development by a pharmaceutical company called Synendos Therapeutics.^[1]^[2]^[3]

References

^ ^a ^b ^c ^d "SYT 510". AdisInsight. 22 January 2024. Retrieved 15 August 2024.
^ ^a ^b ^c "Delving into the Latest Updates on SYT-510 with Synapse". Synapse. 4 August 2024. Retrieved 15 August 2024.
^ ^a ^b ^c Gertsch J, Chicca A (July 2024). "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem: e202400397. doi:10.1002/cbic.202400397. PMID 38958639. Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain.
^ ^a ^b ^c Therapeutics, Synendos (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". PR Newswire. Retrieved 15 August 2024.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.